Shots:
- Following the US FDA approval, the EC has approved Eurneffy (2mg) for type I allergic reactions (anaphylaxis) in adults & children (≥30kg). It will be available in Q4’24 through undisclosed pharmaceutical partner
- The approval was supported by the results from a study, involving ~1200 administrations among >700 subjects, along with studies and peer-reviewed literature supporting these results
- The study assessed PK/PD of Eureffy (2mg) under various conditions such as single and repeat dosing, self-administration, pediatric dosing & in nasal conditions like congestion and rhinorrhea due to allergens or infections like cold/flu
Ref: ARS Pharmaceuticals | Image: ARS Pharmaceuticals | Press Release
Related News:- Roche’s PiaSky Receives the EC’s Approval to Treat Paroxysmal Nocturnal Haemoglobinuria (PNH)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
